Shots:

• The P-I CHRYSALIS study involves assessing of amivantamab (RP2D of 1050 mg [1400 mg for a patient weight of ≥80 kg]) as a monothx. and in combination with lazertinib in 460 patients with metastatic or unresectable NSCLC and EGFR exon 20 insertion mutations whose disease progressed on or after platinum-based CT
• Results: ORR (40%); mPFS (8.3 mos.); mOS (22.8 mos.)- clinical benefit rate (74%)- mDoR (11.1 mos.). The data showed robust activity and durable responses with a tolerable and manageable safety profile
• The company has filed regulatory submissions in the US and EU seeking approval of amivantamab

 ­ Ref: PR Newswire | Image: Janssen